Literature DB >> 16877740

Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.

Bernardo Bonanni, Debora Macis, Patrick Maisonneuve, Harriet A Johansson, Giacomo Gucciardo, Pasquale Oliviero, Roberto Travaglini, Maria G Muraca, Nicole Rotmensz, Umberto Veronesi, Andrea U Decensi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16877740     DOI： 10.1200/JCO.2006.06.8072

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  35 in total

1.  CYP2D6*4 allele and breast cancer risk: is there any association?

Authors:  Ana Fernández-Santander; Miguel del Saz Sánchez; Armando Tejerina Gómez; Fernando Bandrés Moya
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

Review 2.  CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.

Authors:  Jonas A de Souza; Olufunmilayo I Olopade
Journal:  Semin Oncol       Date:  2011-04       Impact factor: 4.929

3.  Germline pharmacogenetics of tamoxifen response: have we learned enough?

Authors:  Zeruesenay Desta; David A Flockhart
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

4.  Breast Cancer Systemic Therapy: The Need for More Economically Sustainable Scientific Strategies in the World.

Authors:  Ahmed Elzawawy
Journal:  Breast Care (Basel)       Date:  2008-11-25       Impact factor: 2.860

5.  A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?

Authors:  Daniel F Hayes; Vered Stearns; James Rae; David Flockhart
Journal:  J Natl Cancer Inst       Date:  2008-04-29       Impact factor: 13.506

6.  Clinical and biomarker predictors of side effects from tamoxifen.

Authors:  Wendy Lorizio; Alan H B Wu; Mary S Beattie; Hope Rugo; Simone Tchu; Karla Kerlikowske; Elad Ziv
Journal:  Breast Cancer Res Treat       Date:  2011-12-30       Impact factor: 4.872

7.  CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

Authors:  Meredith M Regan; Brian Leyland-Jones; Mark Bouzyk; Olivia Pagani; Weining Tang; Roswitha Kammler; Patrizia Dell'orto; Maria Olivia Biasi; Beat Thürlimann; Maria B Lyng; Henrik J Ditzel; Patrick Neven; Marc Debled; Rudolf Maibach; Karen N Price; Richard D Gelber; Alan S Coates; Aron Goldhirsch; James M Rae; Giuseppe Viale
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

8.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.

Authors:  Jean E Abraham; Mel J Maranian; Kristy E Driver; Radka Platte; Bolot Kalmyrzaev; Caroline Baynes; Craig Luccarini; Mitul Shah; Susan Ingle; David Greenberg; Helena M Earl; Alison M Dunning; Paul D P Pharoah; Carlos Caldas
Journal:  Breast Cancer Res       Date:  2010-08-23       Impact factor: 6.466

Review 10.  CYP2D6 and tamoxifen: DNA matters in breast cancer.

Authors:  Janelle M Hoskins; Lisa A Carey; Howard L McLeod
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.